Effects of imidazoline-like drugs on liver and adipose tissues, and their role in preventing obesity and associated cardio-metabolic disorders

No abstract is available for this paper.

• Publication year

  2019

• Venue

  International Journal of Obesity

• Publication date

  2019-03-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41366-019-0342-zPMID 30926950
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of bioimpedance spectroscopy and X-Ray micro-computed tomography for total fat volume measurement in mice

  2017cited by this paper
• Brown adipose tissue does not seem to mediate metabolic adaptation to overfeeding in men

  2017cited by this paper
• Brown adipose tissue: The heat is on the heart.

  2016cited by this paper
• Differential Role of Adipose Tissues in Obesity and Related Metabolic and Vascular Complications

  2016cited by this paper
• Adipose tissue in control of metabolism.

  2016cited by this paper
• CALL FOR PAPERS Novel Aspects of Adipocyte Biology Imidazoline-like drugs improve insulin sensitivity through peripheral stimulation of adiponectin and AMPK pathways in a rat model of glucose intolerance

  2015cited by this paper
• Imidazoline-like drugs improve insulin sensitivity through peripheral stimulation of adiponectin and AMPK pathways in a rat model of glucose intolerance.

  2015cited by this paper
• Synthesis and biological evaluation of 2-aryliminopyrrolidines as selective ligands for I1 imidazoline receptors: discovery of new sympatho-inhibitory hypotensive agents with potential beneficial effects in metabolic syndrome.

  2015cited by this paper
• Brown adipose tissue and its therapeutic potential

  2014cited by this paper
• AMPK, insulin resistance, and the metabolic syndrome.

  2013cited by this paper
• AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: implications for obesity.

  2013cited by this paper
• Emerging role of AMP-activated protein kinase in endocrine control of metabolism in the liver.

  2013cited by this paper
• A New Pyrroline Compound Selective for I1-Imidazoline Receptors Improves Metabolic Syndrome in Rats

  2013cited by this paper
• The metabolic syndrome.

  2013cited by this paper
• Evaluation of Adiposity-Related Biomarkers as Metabolic Syndrome Indicators

  2013cited by this paper
• Effects of Renal Denervation on Sympathetic Activation, Blood Pressure, and Glucose Metabolism in Patients with Resistant Hypertension

  2012cited by this paper
• PPARγ agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein.

  2012cited by this paper
• Adiponectin: Regulation of its production and its role in human diseases

  2012cited by this paper
• The insulin sensitizing effects of PPAR-γ agonist are associated to changes in adiponectin index and adiponectin receptors in Zucker fatty rats.

  2012cited by this paper
• Novel amino-pyrroline derivatives, and use thereof in the prevention and/or treatment of metabolic syndrome

  2012cited by this paper
• Change in Sympathetic Nerve Firing Pattern Associated with Dietary Weight Loss in the Metabolic Syndrome

  2011cited by this paper
• Effects of Renal Sympathetic Denervation on Blood Pressure, Sleep Apnea Course, and Glycemic Control in Patients With Resistant Hypertension and Sleep Apnea

  2011cited by this paper
• Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension: A Pilot Study

  2011cited by this paper
• Attenuated baroreflex control of sympathetic nerve activity in obese Zucker rats by central mechanisms

  2010cited by this paper
• Blunted sympathetic neural response to oral glucose in obese subjects with the insulin-resistant metabolic syndrome.

  2009cited by this paper
• The complex interaction between overweight, hypertension, and sympathetic overactivity.

  2009cited by this paper
• Weight Loss May Reverse Blunted Sympathetic Neural Responsiveness to Glucose Ingestion in Obese Subjects With Metabolic Syndrome

  2009cited by this paper
• Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.

  2008cited by this paper
• PRDM16 controls a brown fat/skeletal muscle switch

  2008cited by this paper
• The sympathetic nervous system and the metabolic syndrome.

  2007cited by this paper
• Progression of coronary and mesenteric vascular dysfunction in Zucker obese and Zucker diabetic fatty rats.

  2006cited by this paper
• Adiponectin – a key adipokine in the metabolic syndrome

  2006cited by this paper
• Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation

  2006cited by this paper
• Baroreflex function: determinants in healthy subjects and disturbances in diabetes, obesity and metabolic syndrome.

  2006cited by this paper
• Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

  2005cited by this paper
• Adiponectin and adiponectin receptors.

  2005cited by this paper
• Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome

  2005cited by this paper
• Cerebrovascular dysfunction in Zucker obese rats is mediated by oxidative stress and protein kinase C.

  2004cited by this paper
• Peripheral, but not central, administration of adiponectin reduces visceral adiposity and upregulates the expression of uncoupling protein in agouti yellow (Ay/a) obese mice.

  2003cited by this paper
• Synthesis and biological evaluation of pyrrolinic isosteres of rilmenidine. Discovery of cis-/trans-dicyclopropylmethyl-(4,5-dimethyl-4,5-dihydro-3H-pyrrol-2-yl)-amine (LNP 509), an I1 imidazoline receptor selective ligand with hypotensive activity.

  2001cited by this paper
• The I1‐imidazoline receptor in PC12 pheochromocytoma cells activates protein kinases C, extracellular signal‐regulated kinase (ERK) and c‐jun N‐terminal kinase (JNK)

  2001cited by this paper
• Coupling of I(1) imidazoline receptors to the cAMP pathway: studies with a highly selective ligand, benazoline.

  2000cited by this paper
• Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB).

  1999cited by this paper
• Effects of clonidine and other imidazole-receptor binding agents on second messenger systems and calcium influx in bovine adrenal chromaffin cells.

  1991cited by this paper
• Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines.

  1984cited by this paper

• Is AMP-activated protein kinase activation a central mechanism of cardio-metabolic outcomes after metabolic and bariatric surgery?

  2026cites this paper
• Synthesis and Structure of Novel Hybrid Compounds Containing Phthalazin-1(2H)-imine and 4,5-Dihydro-1H-imidazole Cores and Their Sulfonyl Derivatives with Potential Biological Activities

  2024cites this paper
• Increased monoamine oxidase activity and imidazoline binding sites in insulin-resistant adipocytes from obese Zucker rats

  2022cites this paper
• Protective effects of the imidazoline-like drug lnp599 in a marmoset model of obesity-induced metabolic disorders

  2021influential citation
• Nischarin Is Not the Functional I1 Imidazoline Receptor Involved in Blood Pressure Regulation

  2021cites this paper